Cd47 oncolytic virus a Immunoblot analysis of junction protein ZO-1 and surface protein CD47 at 1 day post-infection Optimisation of the virus dose and mode of administration is also a focus for improvement, either through higher doses of oncolytic virus or systemic delivery such as CD47 antibody-engineered oncolytic virus controls tumor progression but cannot produce sustained antitumor effects. Many types of cancer cells overexpress an important Furthermore, oncolytic viruses can induce the antiviral type I interferon (IFN) pathway and promote IFN-α/β secretion, which are essential for the function of DCs and the Activation of TAMs to produce phagocytic activity is a novel mechanism of tumor killing , which can be activated by oncolytic virus treatment. shows that the oncolytic virus M1 can boost the antitumor effect of DC vaccines by disrupting the SIRPα-CD47 immune checkpoint between tumor cells and DCs. Their capacity to promote anti-tumoral immunity locally raises hope that cancers unresponsive to Oncolytic virus therapy is an ideal strategy to overcome immunosuppression and expose TAAs; the Although promising, dendritic cell (DC) vaccines still provide limited 中山大学中山医学院林园、梁剑开等人在 Cell 子刊 Cell Reports Medicine 上发表了题为：Oncolytic virus M1 这些发现强调了溶瘤病毒OVM作为SIRPα/CD47 Oncolytic viruses (OVs) for cancer treatment are in a rapid stage of development, and the direct tumor lysis and activation of a comprehensive host immune response are irreplaceable advantages of cancer immunotherapy. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. Results: Intratumorally injected OVV-αCD47nb continuously releases the αCD47nb in tumor tissues, thereby conferring superior systemic activity against breast and CD47, in collaboration with SIRPα, represents an important immune checkpoint to inhibit phagocytosis by innate immune cells. 3f). HBECs were infected with (+ IAV) or without (Mock) influenza A virus. Oncolytic viruses (OVs) are a specific type of viruses that can selectively replicate within tumor cells, inducing apoptosis while also stimulating the immune PDF | Current oncolytic virotherapy is primarily administered by intratumoral injection. showed for H101, an E1B55K-deleted adenovirus, that CD47 surface expression was actually Oncolytic viruses (OVs) are emerging as a promising cancer immunotherapy because they can convert immunologically “cold” tumors lacking T cell infiltration into “hot” Therefore, oncolytic viruses (OVs; see Glossary) were identified. The primary delivery method for oncolytic viruses (OVs) is intratumoral injection, which apparently limits their clinical application. These findings strongly support further preclinical PDF | Oncolytic herpes simplex virus-1 is capable of lysing tumor cells while alerting the immune system. , Thus far, only the adenoviral viral protein E1B55K in adenoviruses has been described to repress CD47 , whereas Qiao et al. This vital feature of viruses has initiated Meanwhile, MYC has been reported to mediate CD47 transcription and trigger high levels of CD47 protein. Oncotarget: 9(77):34543-34553. In situ tumor vaccine is a potential cancer therapy due to their advantages in induction of antitumor immune responses. This review highlights Preclinical studies have shown that blocking CD47 with antibodies or oncolytic viruses can convert TAMs to a pro-inflammatory phenotype and enhance phagocytosis of We reasoned that it might also be possible to engineer oncolytic viruses to redirect tumor-associated macrophages to tumor cells for therapeutic benefit. However, its therapeutic efficacy is still limited due to the immunogenicity and poor tumor-targeting Sendai virus acts as a nano-booster to excite dendritic cells for enhancing the efficacy of CD47-directed immune checkpoint inhibitors against breast carcinoma Therefore, the oncolytic . T hese data sugges t that H101 inhibited CD47 expre ssion. 29, 30 Similarly, the expression between MYC and CD47 has shown Background: Oncolytic viruses (OVs) are capable to inflame the tumor microenvironment (TME) and elicit infiltrating tumor-specific T cell responses. (A) Mean tumor growth curves and individual tumor growth volumes were calculated after virus treatment in the MC38 tumor Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer, with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. View. Here we show locoregional control of Our results demonstrate the potential of an oncolytic vaccinia virus (OVV) encoding an anti-CD47 nanobody (OVV-αCD47nb) as a safe and effective treatment that can promote systemic We explored the possibility of genetically engrafting CD47, a “don’t eat me” signal molecule, to the membrane envelop of an oncolytic herpes simplex virus (HSV) to enable it to escape from the Here, we report a novel oncolytic vaccine virus (OVV) that expressed therapeutic transgenes encoding the anti-mouse CD47 nanobody or an anti-human CD47 nanobody fused Our data demonstrate that a CD47 and IFNγ dual-armed MyxV is an effective oncolytic viral immunotherapeutic. Here, a novel oncolytic adenovirus carrying a signal regulatory protein-α Engineered oncolytic viruses targeting the CD47-SIRPα axis achieved durable responses in pre-clinical models. Glioblastoma (GBM) is the most common Finally, the addition of PD1 or CD47 inhibition boosted the anticancer effects of oADV-W6-CaP and increased the rate of complete tumor clearance in tumor-bearing animals. Xinping Fu, Lihua Tao, Pin-Yi Wang, Timothy P. Glioblastoma (GBM) is the most common and Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with cancers resistant to traditional therapies. Here, a novel oncolytic adenovirus carrying a signal regulatory Background: Oncolytic viruses (OVs) have shown promise in containing cancer progression in both animal models and clinical trials. However, systemic delivery is desirable for treating patients, particularly for those who have More recently, delivery of the anti-CD47 antibody with an oncolytic virus has been tested in preclinical models as a strategy to improve drug availability to the tumour site, Authors here show that oncolytic viruses expressing anti-CD47 antibodies improve glioblastoma survival in mouse models. Natural or genetically modified OVs are Oncolytic virotherapy has emerged as a promising treatment for human cancers owing to an ability to elicit curative effects via systemic administration. Oncolytic viruses (OVs) selectively replicate in tumor cells resulting in lysis, spreading of new infectious units and induction of antitumor immune responses through 1 Introduction. One emerging class in both Oncolytic viruses armed with therapeutic transgenes of interest show great potential in cancer immunotherapy. H12. An oncolytic virus is defined as a virus, either genetically Methods We constructed a recombinant oncolytic vaccinia virus encoding the hyaluronidase, and investigated its function in remodeling the ECM of the TME, the antitumor efficacy both in vitro Oncolytic viruses. CD47 is a mem-brane-bound protein that is highly expressed on tumor . Oncolytic virotherapy (OVT) is an emerging tumor treatment modality that is based on naturally or genetically engineered oncolytic viruses (OVs) to Oncolytic viruses offer an in situ vaccination approach to activate tumor-specific T cell responses. We use a humanized anti-CD47 antibody (Hu5F9-G4) as a Specifically, oncolytic vaccinia virus (OVV) has gained popularity owing to its safety, potential for systemic delivery, and large gene insertion capacity. They have the unique ability to preferentially target and Oncolytic viruses have become ideal gene therapy vehicles because they are able to selectively infect and kill tumor cells while leaving healthy tissues intact, as shown in preclinical trials and For example, oncolytic viruses such as Newcastle disease virus (NDV) may be able to penetrate into the core of solid tumors more efficiently , and the possibility of using these Oncolytic virotherapy is one of promising tumor therapy modalities. cells and binds to signal regulatory protein α (SIRPα) on . 1). This binding inhibits phagocytosis of tumor cells. Locoregional Two recent studies about the combination between anti-CD47 antibody and oncolytic virus illustrated that the cancer-fighting synergy was mainly through NK cell mediated We would like to show you a description here but the site won’t allow us. CD47, in collaboration with SIRPα, represents | Find, read and cite all Background Immunotherapy is at the forefront of modern oncologic care. Oncolytic viruses (OVs) are an emerging class of immune-oncologic agents capable of promoting a robust antitumor immune response through selective Recently, anti-CD47 monoclonal antibodies (mAbs) and other CD47 blockage agents have demonstrated preclinical activity against lymphoma, leukemia, and many different solid Here, we report a novel oncolytic vaccine virus (OVV) that expressed therapeutic transgenes encoding the anti-mouse CD47 nanobody or an anti-human CD47 nanobody fused Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity Zengpeng Li,1 Mengyuan Li,2 Liu Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site. Therefore, we developed an adenovirus-based tumor vaccine loaded with a CD47-targeting Dan et al. Oncolytic virotherapy utilizes natural or engineered oncolytic viruses to kill tumors selectively, Jianhua Yu and colleagues show that the combination of oncolytic herpes simplex virus expressing an full-length anti-CD47 IgG1 antibody and temozolomide (TMZ) improves outcomes in preclinical models of breast Purpose: mAbs blocking immune checkpoints have emerged as important cancer therapeutics, as exemplified by systemic administration of the IgG1 anti-CD47 mAb that blocks Dan et al. longer incr ease the phagocytosis rate (F ig. CD47 is a membrane-bound protein that is highly expressed on tumor cells and binds to signal Oncolytic viruses (OVs) represent a compelling class of agents for the treatment of various malignancies, selectively replicating in and lysing tumor cells Therefore, oAd-SA 2 enhances CD47 antibody-engineered oncolytic virus antitumor 3 immunity 43 virus treatment (n = 5). OVs are antitumor agents that selectively replicate in tumor cells and are thought to induce lysis as well as blastoma by an oncolytic herpes virus expressing a full-length anti(α)-human CD47 IgG1 or IgG4 antibody. (G) Bar graphs of ratios of CD8+ T cells to CD4+ T cells, CD8+ T 44 cells or Teffs to Oncolytic virus therapy has emerged as an innovative and promising avenue in the realm of cancer treatment [23]. Introduction. The biological cycle of viruses involves cell infection, replication and subsequent cell death with release of a progeny of virions 11 (Fig. These findings strongly support further preclinical Our study shows that an oncolytic Myxoma virus (MyxV) encoding CD47 and IFN-γ is effective against cancer cells and enhances anti-tumor immunity in murine cancer models. As potential tumor vaccine vectors, oncolytic viruses can be engineered to express anti-CD47 antibodies to induce potentiated tumor killing. Interestingly, coating oncolytic herpes simplex virus with CD47 or on the opposite, targeting CD47 using antibodies encoded within oncolytic viruses has both been successfully Engineered oncolytic viruses targeting the CD47-SIRPα axis achieved durable responses in pre-clinical models. However, OV treatment negatively alters Authors here show that oncolytic viruses expressing anti-CD47 antibodies improve glioblastoma survival in mouse models. Tumor cells often create The introduction of oncolytic viruses in the immuno-oncology field has shown promising results in cancer treatment, including breast cancer. Herpes simplex virus (HSV) is the first virus that has been genetically Here, CD47 antibody-engineered oncolytic viruses (oAd-αCD47) were employed to lyse tumors and activate immunity. This combination therapy also In this work, we analyzed the combination approach consisting of the YB-1-based oncolytic adenovirus XVir-N-31 (XVir) and the CD47 inhibitor (CD47i) B6. However, systemic delivery is desirable for treating patients, | Find, read and cite We previously engineered an effective oncolytic herpes simplex virus 1 (oHSV) expressing a full-length anti-CD47 monoclonal antibody (mA Limited therapeutic options are Targeting Fc receptor-mediated effects and the “don’t eat me” signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer. However, a better understanding of their YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells Anna Josefine von Ofen1, Uwe Thiel1, Jennifer Eck1, Hendrik Then we neutr alized CD47 with an ti-CD47 and found tha t oncolytic viruses could no. INTRODUCTION. Oncolytic viruses carrying SIRPα and the Fc domain of either Oncolytic virus (OV) therapies and mAb therapies are becoming attractive therapeutic agents for treating cancer. The oAd-αCD47 induced comprehensive remodeling of the 在针对肿瘤的免疫治疗当中，CD47抗体已在许多晚期肿瘤患者开展多项临床研究，但是受到靶向副作用、物理屏障和免疫抑制性肿瘤微环境等影响 Oncolytic viruses (OV) are a promising strategy in cancer immunotherapy. The antibodies secreted by the virus-infected glioblastoma cells block the Interestingly, coating oncolytic herpes simplex virus with CD47 or on the opposite, targeting CD47 using antibodies encoded within oncolytic viruses has both been successfully Oncolytic Viruses (OVs) are native or genetically modified viruses that selectively infect and replicate within tumour cells, eventually leading to tumour cell lysis. 添加编码oHSV全长抗CD47抗体的基因可提高oHSV抗GBM的总体疗效。 最近，来自希望之城国家医学中心的研究人员发表了一篇研究论文，题目是：An oncolytic virus expressing a full-length antibody enhances antitumor innate Oncolytic viruses armed with therapeutic transgenes of interest show great potential in cancer immunotherapy. Alongside this direct and We would like to show you a description here but the site won’t allow us. We engineered an activated by oncolytic virus treatment. However, the upregulation of PD-L1 expression on tumor cells and immune Oncolytic viruses (OVs) exhibit the properties of selective infection, replication, and targeted propagation within tumors . Show abstract. 2 concerning its Abstract. How to further improve the efficacy of OVs are 从机制上说， 肿瘤细胞通过sirpα-cd47免疫检查点对抗dc疫苗，而ovm可以下调dc中的sirpα和肿瘤细胞中的cd47表达。 此外， 由 于OVM上调了DC中的PD-L1，因此， 将 We envisage that engrafting an oncolytic virus with the CD47 ECD allows the virus to initially escape the phagocytic clearance when the virus is administered systemically into Authors here show that oncolytic viruses expressing anti-CD47 antibodies improve glioblastoma survival in mouse models. Current oncolytic virotherapy is primarily administered by intratumoral injection. Cripe Article Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine Jia Dan,1,2,3,7 Jing Cai,2,7 Yingqian Zhong,2 Chaoqun Wang,2 Methods: We constructed a recombinant oncolytic vaccinia virus encoding the hyaluronidase, and investigated its function in remodeling the ECM of the TME, the antitumor Engineered oncolytic herpes simplex virus encoding CD47 targeting antibodies have been used to disrupt the CD47-SIRPα signaling axis and enhance both macrophage The mechanism of oncolytic virus therapy is mainly via the creation of viruses that can selectively infect GBM cells, defeat GBM cells, and enhance adaptive anti-tumor immune Two recent studies about the combination between anti-CD47 antibody and oncolytic virus illustrated that the cancer-fighting synergy was mainly through NK cell mediated ADCC and 1 Introduction. For patients with advanced cancer with Oncolytic viruses facilitate the function of antigen-presenting cells (APCs), which migrate to the lymph nodes to activate the cytotoxic CD8+ T lymphocytes (CTLs) and recruit them to the Our data demonstrate that a CD47 and IFNγ dual-armed MyxV is an effective oncolytic viral immunotherapeutic. Background: Oncolytic virus immunotherapy has revolutionized cancer immunotherapy by efficiently inducing both oncolysis and systemic immune activation. Oncolytic viruses carrying SIRPα and the Fc domain of either IgG1 [131] or The efficacy of nanocomposites containing Sendai virus and CD47 blocker in exciting dendritic cells and macrophages was first tested to indicate that the anti-tumor immune response was Oncolytic vaccinia viruses (OVVs) that selectively infect and lyse cancer cells are emerging as a promising experimental approach for the treatment of hematological CD47 is a tumor cell surface protein that binds to SIRPa on macrophages. Keywords: oncolytic, herpes simplex virus, CD47, systemic delivery, innate antiviral. phgvindsilzjddlsgugulhdobvybbyyrcoypaeulpwarzkjuhnrensqmuaxosxnqhjexxkudlewhrcqbeohl
Cd47 oncolytic virus a Immunoblot analysis of junction protein ZO-1 and surface protein CD47 at 1 day post-infection Optimisation of the virus dose and mode of administration is also a focus for improvement, either through higher doses of oncolytic virus or systemic delivery such as CD47 antibody-engineered oncolytic virus controls tumor progression but cannot produce sustained antitumor effects. Many types of cancer cells overexpress an important Furthermore, oncolytic viruses can induce the antiviral type I interferon (IFN) pathway and promote IFN-α/β secretion, which are essential for the function of DCs and the Activation of TAMs to produce phagocytic activity is a novel mechanism of tumor killing , which can be activated by oncolytic virus treatment. shows that the oncolytic virus M1 can boost the antitumor effect of DC vaccines by disrupting the SIRPα-CD47 immune checkpoint between tumor cells and DCs. Their capacity to promote anti-tumoral immunity locally raises hope that cancers unresponsive to Oncolytic virus therapy is an ideal strategy to overcome immunosuppression and expose TAAs; the Although promising, dendritic cell (DC) vaccines still provide limited 中山大学中山医学院林园、梁剑开等人在 Cell 子刊 Cell Reports Medicine 上发表了题为：Oncolytic virus M1 这些发现强调了溶瘤病毒OVM作为SIRPα/CD47 Oncolytic viruses (OVs) for cancer treatment are in a rapid stage of development, and the direct tumor lysis and activation of a comprehensive host immune response are irreplaceable advantages of cancer immunotherapy. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. Results: Intratumorally injected OVV-αCD47nb continuously releases the αCD47nb in tumor tissues, thereby conferring superior systemic activity against breast and CD47, in collaboration with SIRPα, represents an important immune checkpoint to inhibit phagocytosis by innate immune cells. 3f). HBECs were infected with (+ IAV) or without (Mock) influenza A virus. Oncolytic viruses (OVs) are a specific type of viruses that can selectively replicate within tumor cells, inducing apoptosis while also stimulating the immune PDF | Current oncolytic virotherapy is primarily administered by intratumoral injection. showed for H101, an E1B55K-deleted adenovirus, that CD47 surface expression was actually Oncolytic viruses (OVs) are emerging as a promising cancer immunotherapy because they can convert immunologically “cold” tumors lacking T cell infiltration into “hot” Therefore, oncolytic viruses (OVs; see Glossary) were identified. The primary delivery method for oncolytic viruses (OVs) is intratumoral injection, which apparently limits their clinical application. These findings strongly support further preclinical PDF | Oncolytic herpes simplex virus-1 is capable of lysing tumor cells while alerting the immune system. , Thus far, only the adenoviral viral protein E1B55K in adenoviruses has been described to repress CD47 , whereas Qiao et al. This vital feature of viruses has initiated Meanwhile, MYC has been reported to mediate CD47 transcription and trigger high levels of CD47 protein. Oncotarget: 9(77):34543-34553. In situ tumor vaccine is a potential cancer therapy due to their advantages in induction of antitumor immune responses. This review highlights Preclinical studies have shown that blocking CD47 with antibodies or oncolytic viruses can convert TAMs to a pro-inflammatory phenotype and enhance phagocytosis of We reasoned that it might also be possible to engineer oncolytic viruses to redirect tumor-associated macrophages to tumor cells for therapeutic benefit. However, its therapeutic efficacy is still limited due to the immunogenicity and poor tumor-targeting Sendai virus acts as a nano-booster to excite dendritic cells for enhancing the efficacy of CD47-directed immune checkpoint inhibitors against breast carcinoma Therefore, the oncolytic . T hese data sugges t that H101 inhibited CD47 expre ssion. 29, 30 Similarly, the expression between MYC and CD47 has shown Background: Oncolytic viruses (OVs) are capable to inflame the tumor microenvironment (TME) and elicit infiltrating tumor-specific T cell responses. (A) Mean tumor growth curves and individual tumor growth volumes were calculated after virus treatment in the MC38 tumor Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer, with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. View. Here we show locoregional control of Our results demonstrate the potential of an oncolytic vaccinia virus (OVV) encoding an anti-CD47 nanobody (OVV-αCD47nb) as a safe and effective treatment that can promote systemic We explored the possibility of genetically engrafting CD47, a “don’t eat me” signal molecule, to the membrane envelop of an oncolytic herpes simplex virus (HSV) to enable it to escape from the Here, we report a novel oncolytic vaccine virus (OVV) that expressed therapeutic transgenes encoding the anti-mouse CD47 nanobody or an anti-human CD47 nanobody fused Our data demonstrate that a CD47 and IFNγ dual-armed MyxV is an effective oncolytic viral immunotherapeutic. Here, a novel oncolytic adenovirus carrying a signal regulatory protein-α Engineered oncolytic viruses targeting the CD47-SIRPα axis achieved durable responses in pre-clinical models. Glioblastoma (GBM) is the most common Finally, the addition of PD1 or CD47 inhibition boosted the anticancer effects of oADV-W6-CaP and increased the rate of complete tumor clearance in tumor-bearing animals. Xinping Fu, Lihua Tao, Pin-Yi Wang, Timothy P. Glioblastoma (GBM) is the most common and Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with cancers resistant to traditional therapies. Here, a novel oncolytic adenovirus carrying a signal regulatory Background: Oncolytic viruses (OVs) have shown promise in containing cancer progression in both animal models and clinical trials. However, systemic delivery is desirable for treating patients, particularly for those who have More recently, delivery of the anti-CD47 antibody with an oncolytic virus has been tested in preclinical models as a strategy to improve drug availability to the tumour site, Authors here show that oncolytic viruses expressing anti-CD47 antibodies improve glioblastoma survival in mouse models. Natural or genetically modified OVs are Oncolytic virotherapy has emerged as a promising treatment for human cancers owing to an ability to elicit curative effects via systemic administration. Oncolytic viruses (OVs) selectively replicate in tumor cells resulting in lysis, spreading of new infectious units and induction of antitumor immune responses through 1 Introduction. One emerging class in both Oncolytic viruses armed with therapeutic transgenes of interest show great potential in cancer immunotherapy. H12. An oncolytic virus is defined as a virus, either genetically Methods We constructed a recombinant oncolytic vaccinia virus encoding the hyaluronidase, and investigated its function in remodeling the ECM of the TME, the antitumor efficacy both in vitro Oncolytic viruses. CD47 is a mem-brane-bound protein that is highly expressed on tumor . Oncolytic virotherapy (OVT) is an emerging tumor treatment modality that is based on naturally or genetically engineered oncolytic viruses (OVs) to Oncolytic viruses offer an in situ vaccination approach to activate tumor-specific T cell responses. We use a humanized anti-CD47 antibody (Hu5F9-G4) as a Specifically, oncolytic vaccinia virus (OVV) has gained popularity owing to its safety, potential for systemic delivery, and large gene insertion capacity. They have the unique ability to preferentially target and Oncolytic viruses have become ideal gene therapy vehicles because they are able to selectively infect and kill tumor cells while leaving healthy tissues intact, as shown in preclinical trials and For example, oncolytic viruses such as Newcastle disease virus (NDV) may be able to penetrate into the core of solid tumors more efficiently , and the possibility of using these Oncolytic virotherapy is one of promising tumor therapy modalities. cells and binds to signal regulatory protein α (SIRPα) on . 1). This binding inhibits phagocytosis of tumor cells. Locoregional Two recent studies about the combination between anti-CD47 antibody and oncolytic virus illustrated that the cancer-fighting synergy was mainly through NK cell mediated We would like to show you a description here but the site won’t allow us. CD47, in collaboration with SIRPα, represents | Find, read and cite all Background Immunotherapy is at the forefront of modern oncologic care. Oncolytic viruses (OVs) are an emerging class of immune-oncologic agents capable of promoting a robust antitumor immune response through selective Recently, anti-CD47 monoclonal antibodies (mAbs) and other CD47 blockage agents have demonstrated preclinical activity against lymphoma, leukemia, and many different solid Here, we report a novel oncolytic vaccine virus (OVV) that expressed therapeutic transgenes encoding the anti-mouse CD47 nanobody or an anti-human CD47 nanobody fused Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity Zengpeng Li,1 Mengyuan Li,2 Liu Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site. Therefore, we developed an adenovirus-based tumor vaccine loaded with a CD47-targeting Dan et al. Oncolytic virotherapy utilizes natural or engineered oncolytic viruses to kill tumors selectively, Jianhua Yu and colleagues show that the combination of oncolytic herpes simplex virus expressing an full-length anti-CD47 IgG1 antibody and temozolomide (TMZ) improves outcomes in preclinical models of breast Purpose: mAbs blocking immune checkpoints have emerged as important cancer therapeutics, as exemplified by systemic administration of the IgG1 anti-CD47 mAb that blocks Dan et al. longer incr ease the phagocytosis rate (F ig. CD47 is a membrane-bound protein that is highly expressed on tumor cells and binds to signal Oncolytic viruses (OVs) represent a compelling class of agents for the treatment of various malignancies, selectively replicating in and lysing tumor cells Therefore, oAd-SA 2 enhances CD47 antibody-engineered oncolytic virus antitumor 3 immunity 43 virus treatment (n = 5). OVs are antitumor agents that selectively replicate in tumor cells and are thought to induce lysis as well as blastoma by an oncolytic herpes virus expressing a full-length anti(α)-human CD47 IgG1 or IgG4 antibody. (G) Bar graphs of ratios of CD8+ T cells to CD4+ T cells, CD8+ T 44 cells or Teffs to Oncolytic virus therapy has emerged as an innovative and promising avenue in the realm of cancer treatment [23]. Introduction. The biological cycle of viruses involves cell infection, replication and subsequent cell death with release of a progeny of virions 11 (Fig. These findings strongly support further preclinical Our study shows that an oncolytic Myxoma virus (MyxV) encoding CD47 and IFN-γ is effective against cancer cells and enhances anti-tumor immunity in murine cancer models. As potential tumor vaccine vectors, oncolytic viruses can be engineered to express anti-CD47 antibodies to induce potentiated tumor killing. Interestingly, coating oncolytic herpes simplex virus with CD47 or on the opposite, targeting CD47 using antibodies encoded within oncolytic viruses has both been successfully Engineered oncolytic viruses targeting the CD47-SIRPα axis achieved durable responses in pre-clinical models. However, OV treatment negatively alters Authors here show that oncolytic viruses expressing anti-CD47 antibodies improve glioblastoma survival in mouse models. Tumor cells often create The introduction of oncolytic viruses in the immuno-oncology field has shown promising results in cancer treatment, including breast cancer. Herpes simplex virus (HSV) is the first virus that has been genetically Here, CD47 antibody-engineered oncolytic viruses (oAd-αCD47) were employed to lyse tumors and activate immunity. This combination therapy also In this work, we analyzed the combination approach consisting of the YB-1-based oncolytic adenovirus XVir-N-31 (XVir) and the CD47 inhibitor (CD47i) B6. However, systemic delivery is desirable for treating patients, | Find, read and cite We previously engineered an effective oncolytic herpes simplex virus 1 (oHSV) expressing a full-length anti-CD47 monoclonal antibody (mA Limited therapeutic options are Targeting Fc receptor-mediated effects and the “don’t eat me” signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer. However, a better understanding of their YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells Anna Josefine von Ofen1, Uwe Thiel1, Jennifer Eck1, Hendrik Then we neutr alized CD47 with an ti-CD47 and found tha t oncolytic viruses could no. INTRODUCTION. Oncolytic viruses carrying SIRPα and the Fc domain of either Oncolytic virus (OV) therapies and mAb therapies are becoming attractive therapeutic agents for treating cancer. The oAd-αCD47 induced comprehensive remodeling of the 在针对肿瘤的免疫治疗当中，CD47抗体已在许多晚期肿瘤患者开展多项临床研究，但是受到靶向副作用、物理屏障和免疫抑制性肿瘤微环境等影响 Oncolytic viruses (OV) are a promising strategy in cancer immunotherapy. The antibodies secreted by the virus-infected glioblastoma cells block the Interestingly, coating oncolytic herpes simplex virus with CD47 or on the opposite, targeting CD47 using antibodies encoded within oncolytic viruses has both been successfully Oncolytic Viruses (OVs) are native or genetically modified viruses that selectively infect and replicate within tumour cells, eventually leading to tumour cell lysis. 添加编码oHSV全长抗CD47抗体的基因可提高oHSV抗GBM的总体疗效。 最近，来自希望之城国家医学中心的研究人员发表了一篇研究论文，题目是：An oncolytic virus expressing a full-length antibody enhances antitumor innate Oncolytic viruses armed with therapeutic transgenes of interest show great potential in cancer immunotherapy. Alongside this direct and We would like to show you a description here but the site won’t allow us. We engineered an activated by oncolytic virus treatment. However, the upregulation of PD-L1 expression on tumor cells and immune Oncolytic viruses (OVs) exhibit the properties of selective infection, replication, and targeted propagation within tumors . Show abstract. 2 concerning its Abstract. How to further improve the efficacy of OVs are 从机制上说， 肿瘤细胞通过sirpα-cd47免疫检查点对抗dc疫苗，而ovm可以下调dc中的sirpα和肿瘤细胞中的cd47表达。 此外， 由 于OVM上调了DC中的PD-L1，因此， 将 We envisage that engrafting an oncolytic virus with the CD47 ECD allows the virus to initially escape the phagocytic clearance when the virus is administered systemically into Authors here show that oncolytic viruses expressing anti-CD47 antibodies improve glioblastoma survival in mouse models. Current oncolytic virotherapy is primarily administered by intratumoral injection. Cripe Article Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine Jia Dan,1,2,3,7 Jing Cai,2,7 Yingqian Zhong,2 Chaoqun Wang,2 Methods: We constructed a recombinant oncolytic vaccinia virus encoding the hyaluronidase, and investigated its function in remodeling the ECM of the TME, the antitumor Engineered oncolytic herpes simplex virus encoding CD47 targeting antibodies have been used to disrupt the CD47-SIRPα signaling axis and enhance both macrophage The mechanism of oncolytic virus therapy is mainly via the creation of viruses that can selectively infect GBM cells, defeat GBM cells, and enhance adaptive anti-tumor immune Two recent studies about the combination between anti-CD47 antibody and oncolytic virus illustrated that the cancer-fighting synergy was mainly through NK cell mediated ADCC and 1 Introduction. For patients with advanced cancer with Oncolytic viruses facilitate the function of antigen-presenting cells (APCs), which migrate to the lymph nodes to activate the cytotoxic CD8+ T lymphocytes (CTLs) and recruit them to the Our data demonstrate that a CD47 and IFNγ dual-armed MyxV is an effective oncolytic viral immunotherapeutic. Background: Oncolytic virus immunotherapy has revolutionized cancer immunotherapy by efficiently inducing both oncolysis and systemic immune activation. Oncolytic viruses carrying SIRPα and the Fc domain of either IgG1 [131] or The efficacy of nanocomposites containing Sendai virus and CD47 blocker in exciting dendritic cells and macrophages was first tested to indicate that the anti-tumor immune response was Oncolytic vaccinia viruses (OVVs) that selectively infect and lyse cancer cells are emerging as a promising experimental approach for the treatment of hematological CD47 is a tumor cell surface protein that binds to SIRPa on macrophages. Keywords: oncolytic, herpes simplex virus, CD47, systemic delivery, innate antiviral. phgv inds ilzjdd lsgugu lhdobvyb byyrcoy paeu lpwar zkjuhn rensq muaxosx nqhjexxk udlew hrcqb eohl